177 related articles for article (PubMed ID: 32759992)
1. Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population.
Fukunaga K; Hishinuma E; Hiratsuka M; Kato K; Okusaka T; Saito T; Ikeda M; Yoshida T; Zembutsu H; Iwata N; Mushiroda T
J Hum Genet; 2021 Feb; 66(2):139-149. PubMed ID: 32759992
[TBL] [Abstract][Full Text] [Related]
2. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.
Dalton R; Lee SB; Claw KG; Prasad B; Phillips BR; Shen DD; Wong LH; Fade M; McDonald MG; Dunham MJ; Fowler DM; Rettie AE; Schuetz E; Thornton TA; Nickerson DA; Gaedigk A; Thummel KE; Woodahl EL
Clin Transl Sci; 2020 Jan; 13(1):147-156. PubMed ID: 31536170
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
[TBL] [Abstract][Full Text] [Related]
4. Potential Minor Haplotypes of CYP2D6 in the Japanese Population.
Masuda M; Fujiwara T; Matsunaga M; Matsumaru T
Drug Metab Lett; 2017 Nov; 11(1):53-59. PubMed ID: 28606035
[TBL] [Abstract][Full Text] [Related]
5. Resequencing
Manoharan A; Shewade DG; Ravindranath PA; Rajkumar RP; Ramprasad VL; Adithan S; Damodaran SE
Pharmacogenomics; 2019 Jul; 20(10):719-729. PubMed ID: 31368850
[No Abstract] [Full Text] [Related]
6. Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization.
Turner AJ; Aggarwal P; Boone EC; Haidar CE; Relling MV; Derezinski AD; Broeckel U; Gaedigk A
J Mol Diagn; 2021 May; 23(5):577-588. PubMed ID: 33631352
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 polymorphisms and the impact on tamoxifen therapy.
Beverage JN; Sissung TM; Sion AM; Danesi R; Figg WD
J Pharm Sci; 2007 Sep; 96(9):2224-31. PubMed ID: 17518364
[TBL] [Abstract][Full Text] [Related]
8. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
9. Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.
Wendt FR; Sajantila A; Moura-Neto RS; Woerner AE; Budowle B
Int J Legal Med; 2018 Jul; 132(4):1007-1024. PubMed ID: 29075918
[TBL] [Abstract][Full Text] [Related]
10. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.
Wang D; Poi MJ; Sun X; Gaedigk A; Leeder JS; Sadee W
Hum Mol Genet; 2014 Jan; 23(1):268-78. PubMed ID: 23985325
[TBL] [Abstract][Full Text] [Related]
11. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model.
Lee SB; Wheeler MM; Patterson K; McGee S; Dalton R; Woodahl EL; Gaedigk A; Thummel KE; Nickerson DA
Genet Med; 2019 Feb; 21(2):361-372. PubMed ID: 29875422
[TBL] [Abstract][Full Text] [Related]
12. Transfer learning enables prediction of CYP2D6 haplotype function.
McInnes G; Dalton R; Sangkuhl K; Whirl-Carrillo M; Lee SB; Tsao PS; Gaedigk A; Altman RB; Woodahl EL
PLoS Comput Biol; 2020 Nov; 16(11):e1008399. PubMed ID: 33137098
[TBL] [Abstract][Full Text] [Related]
13. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.
Muroi Y; Saito T; Takahashi M; Sakuyama K; Niinuma Y; Ito M; Tsukada C; Ohta K; Endo Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2014; 29(5):360-6. PubMed ID: 24647041
[TBL] [Abstract][Full Text] [Related]
15. Nanopore sequencing of the pharmacogene
Liau Y; Maggo S; Miller AL; Pearson JF; Kennedy MA; Cree SL
Pharmacogenomics; 2019 Sep; 20(14):1033-1047. PubMed ID: 31559921
[No Abstract] [Full Text] [Related]
16. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Saito T; Gutiérrez Rico EM; Kikuchi A; Kaneko A; Kumondai M; Akai F; Saigusa D; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Dec; 33(6):250-257. PubMed ID: 30366777
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
[TBL] [Abstract][Full Text] [Related]
19. Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.
Qiao W; Yang Y; Sebra R; Mendiratta G; Gaedigk A; Desnick RJ; Scott SA
Hum Mutat; 2016 Mar; 37(3):315-23. PubMed ID: 26602992
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen.
Hu XX; Zhou Q; Lan T; Huang XX; Liang BQ; Dai DP; Cai JP; Hu GX
J Pharm Pharmacol; 2016 Jun; 68(6):819-25. PubMed ID: 27109434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
